Alexion Pharmaceuticals, Inc. (ALXN)
-NasdaqGS 93.35 
0.96(1.04%) 00:57 SGT - Nasdaq Real Time Price
| Prev Close: | 92.39 |
|---|
| Open: | 93.84 |
|---|
| Bid: | 93.65 x 100 |
|---|
| Ask: | 93.73 x 200 |
|---|
| 1y Target Est: | 116.55 |
|---|
| Beta: | 0.4 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 93.26 - 95.85 |
|---|
| 52wk Range: | 81.82 - 119.54 |
|---|
| Volume: | 1,798,420 |
|---|
| Avg Vol (3m): | 1,458,150 |
|---|
| Market Cap: | 18.22B |
|---|
| P/E (ttm): | 64.30 |
|---|
| EPS (ttm): | 1.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Gilead Presents Idelalisib DataZacks(Wed, 19 Jun)
- Stocks Open Down In Firm Trade; Adobe Climbs, La-Z-Boy Lollsat Investor's Business Daily(Wed, 19 Jun)
- 3 Healthcare Stocks to Keep an Eye Onat Motley Fool(Wed, 19 Jun)
- An Interview With Elemer Piros: A Strong Year For Biotechs, Looking From The Halfway Pointat Seeking Alpha(Tue, 18 Jun)
- The Zacks Analyst Blog Highlights: Myriad Genetics, Anika Therapeutics, Biogen Idec , Alexion Pharmaceuticals and Cabot Oil & GasZacks(Tue, 18 Jun)
- Amgen Xgeva Label ExpandedZacks(Tue, 18 Jun)
- Alexion Breaks Ground on New Global HeadquartersBusiness Wire(Tue, 18 Jun)
- Myriad: End to Legal Battle over PatentsZacks(Tue, 18 Jun)
- Myriad's Bearish Dive Shows Biotech Leaders Stallingat Investor's Business Daily(Fri, 14 Jun)
- Alexion drug gets breakthrough therapy statusAP(Wed, 29 May)
Key Statistics
| Forward P/E (1 yr): | 28.56 |
|---|
| P/S (ttm): | 14.68 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.68 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | 1.28 |
|---|
Business Summary
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products.
View More